© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
December 29, 2021
Gerald L. Andriole, MD, and co-authors recently presented a study at the 2021 Society of Urologic Oncology Annual Meeting that investigates the novel imaging modality 18F-Fluciclovine PET scan for patients with biochemically recurrent prostate cancer.
December 22, 2021
“We do have a long way to go across the United States,” says Scott E. Eggener, MD.
“There was a point when people thought a trial [would] not be necessary because the answers [were] so clear cut. But obviously, more than just 1 person feels that these are not so clear-cut answers,” says Badar M. Mian, MD, FACS.
December 16, 2021
“One center would report 0.5% infection after transrectal. Another colleague may report 10%. That's a huge gap. And we have to understand why that gap is. The only way to find out will be through these randomized, controlled trials,” says Badar M. Mian, MD, FACS.
December 13, 2021
We have a lot of work to do to define how to optimize the integration of this therapy into what we call ‘advanced prostate cancer’,” says Michael J. Morris, MD.
December 12, 2021
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
December 11, 2021
“The thought [for transperineal biopsy] is that if you can avoid introducing some rectal bacteria into the tissue, that we may be able to totally avoid or at least minimize the post-biopsy infections,” says Badar M. Mian, MD, FACS.
December 10, 2021
"It's comforting to know that the vast majority of patients will meet criteria for [lutetium PSMA], and therefore hopefully be able to receive that type of therapy," says Scott. T. Tagawa, MD, MS, FACP.
December 09, 2021
“We need to be aware of what patients are having to pay out of pocket, how it can impact their overall quality of life, [and] how can it impact their ability to pay for other necessities in life,” says Kelvin A. Moses, MD, PhD, FACS.
December 08, 2021
“[Polygenic risk scores] will help augment PSA screening and other tools to really figure out when we should initiate prostate cancer screening in men and how frequently that screening should occur,” says Isla Garraway, MD, PhD.